Vered Lev

Vered Lev has extensive work experience in the field of CMC (Chemistry, Manufacturing, and Controls) in the biotechnology industry. Vered has held various roles in different companies.

Vered worked at BiomX Inc from September 2018 to May 2020. Vered started as the CMC Director, where they led the Development and GMP manufacturing facility as well as the formulation and production unit. Vered'sresponsibilities included the development and manufacturing of phages for clinical studies. Later, they became the VP CMC, and their current position's end date is not specified.

Prior to BiomX Inc, Vered worked at OPKO Biologics Ltd. Vered held multiple positions during their tenure there. From September 2011 to September 2012, they worked as a Senior Scientist. Then, they became the Director of Chemistry, where they led CMC teams and managed DS and DP production from pre-clinical stages to GMP clinical phases with global CMOs. Vered also led pre-formulation and formulation development for liquid and freeze-drying DP with several CROs. In 2018, they were promoted to the Head of Chemistry and Project Manager, a role they held until May 2020.

Overall, Vered Lev has a strong background in CMC, particularly in leading teams, managing manufacturing facilities, and overseeing formulation and production for clinical studies.

Vered Lev holds a Ph.D. in Organic Chemistry with a focus on peptides and small molecules from the Weizmann Institute of Science, which they obtained from 2002 to 2007. Following their doctoral studies, they pursued post-doctoral positions at the Weizmann Institute of Science. From 2007 to 2010, they worked as a post-doctoral associate in the Department of Biological Chemistry. Subsequently, from 2010 to 2011, they continued their post-doctoral work at the Weizmann Institute of Science, this time in the Department of Organic Chemistry.